To begin, Morphic invests on oral integrin drugs. Integrins are protein structures that are involved in the attachment of cells (like T cells) to other cells. According to Morphic, its oral drugs that target this protein family can help transform the care for patients with chronic illnesses such as fibrosis and cancer, therefore revolutionizing the treatment for genetic diseases.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
What is behind the decline in MORF stock?
There was a sudden decrease in stock price a day after the stock more than doubled after the company’s release of its fourth quarter of earning report. Morphic Holding’s stock market losses are likely the result of two factors. First, it’s possible that some investors may want to liquidate their shares following yesterday’s flash rally. Secondly, it plans to sell common stock in a public offering.
Morphic Holding announced it will issue shares worth $200 million in a public offering. The company also announced 30-day options for its underwriters to acquire up to $30 million in additional shares. The proceeds of the transaction will be used to fund the clinical development of the pipeline candidates.
MORFposted lower than expected revenues and a wider-than-expected loss for the fiscal year 2020. In addition, the biopharmaceutical company publicly released its clinical developments and financial integration with big pharma, sky-rocketing the stock price of the company. On March 1st, MORF stock rose by 130.8%leading MORF share price to move at $84.85.
Morphic has a partnership with Janssen Pharmaceuticals (a daughter company of Johnson & Johnson), which focuses on developing integrin medicines for diseases in which there are few appropriate therapeutic options such as cystic fibrosis and cancer. Morphic announced that it has expanded this partnership with the pharma company further increasing the funding needed for cell adhesion therapy.
If Morphic can deliver a new oral integrin medication that has exploding demands, MORF stock could have serious capital gain. If the company has halted trials, MORF shares could have an incredible plummet. Hence the trial period is extremely significant period in deciding the stock valuation of Morphic stocks.